Key facts
- It has raised $20.0M; the latest was Later Stage VC ($20.0M) in Dec 2025.
- Notable investors include Bayern Kapital, Highlight Capital, BaseLaunch, BiomedVC, University Hospital Wuerzburg — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for T-Curx
- ·The full record, as it builds
Funding rounds
No funding rounds for T-Curx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About T-Curx
Developer of a new generation of T cells intended for personalized cancer immunotherapy. The company's cell technology platform includes virus-free gene transfer and optimizes the binding of chimeric-antigen-receptors to its antigen using a new and proprietary format, enabling healthcare professionals to prevent an excessive reaction of the immune system.
- Sector
- Healthcare
- HQ
- Wuerzburg, Germany
- Founded
- 2017
- Employees
- 1
- Website
- t-curx.com/
- Ownership
- Privately Held (backing)
T-Curx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in T-Curx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on T-Curx in its N-PORT filings yet. We sweep new filings monthly.